We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Xeljanz

News List

Pfizer's Xeljanz scores EU approval for active psoriatic arthritis pharmafile
July 06, 2018
With the decision, Xeljanz becomes the first and only oral Janus kinase inhibitor to be approved in the European Union (EU) for the treatment of adults with active PsA.
Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers pharmaphorum
March 12, 2018
Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended a licence in ulcerative colitis.
Pfizer’s Xeljanz wins US nod for psoriatic arthritis pharmatimes
December 19, 2017
Pfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis (PsA) who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Previous page 1 2 Next page